StockGuide AI
Aktien verfolgen
EN RU ES DE
Centessa Pharmaceuticals

Centessa Pharmaceuticals

Preis: 39.77

Unternehmen und Geschäftsmodell

Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs. Its core products include a pipeline of drug candidates targeting various diseases, primarily in oncology and rare diseases. The company operates through multiple business segments, emphasizing research and development to advance its therapeutic offerings. Major revenue sources are expected to stem from future product launches and collaborations with other pharmaceutical entities.

Anlageprofil

The investment profile of Centessa Pharmaceuticals is more aligned with growth investors, given its focus on developing new therapies and the potential for future revenue generation. However, the high risk associated with its clinical-stage status may deter conservative investors. The stock may appeal to those with a longer investment horizon, as the company seeks to establish its market presence.

Offizielle Website

Fundamentale Kennzahlen (experimentell)

EPS (TTM) — Gewinn pro Aktie der letzten 12 Monate, $
-1.78 Risiko
EPS-Überraschung
-36.8% schlechter als erwartet
20d Volatilität
0.2% stabil
FMP / FinFeed-Daten aktualisiert: 2026-06-11
Empf.: Verkaufen Potenzial: 40 Risiko: 69 Aktualisiert: 2026-06-11 05:16
Wie die Empfehlung funktioniert
Warum KI so denkt:
Weak fundamentals and high risk limit upside potential.

Im Portfolio verfolgen

Preischart

KI-Empfehlung Analystenprognose Kalenderereignis Positives Signal Negatives Signal Neutral / Update Halten / informativ B My buy S My sell
Änderungen der AI-Empfehlung
Datum Vorher Nachher Grund
2026-06-09 02:36 Halten Verkaufen Weak fundamentals and high risk limit upside potential.
2026-06-01 02:34 Verkaufen Halten Weak fundamentals and high volatility signal caution.
2026-05-16 02:53 Halten Verkaufen Weak fundamentals and high volatility raise concerns.
Analystenprognosen
Datum Analyst Action Ziel Preis damals
2026-04-20 09:12 Wells Fargo Bewertung gesenkt — → 42 39.66
2026-02-23 21:07 Wolfe Research Aktualisieren — → 40 25.49
2026-01-29 14:25 Truist Financial Ziel erhöht 33 → 38 24.73